Summary
We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, healthy Spanish Caucasian subjects, based on the enantiomeric S/R mephenytoin ratio in urine collected 0–8 h and 24–32 h after intake of the racemic drug.
Five of the subjects were PM (1.34%, 95% confidence interval 0.18–2.59%), a prevalence lower than in 6 other Caucasian populations, but only significantly lower than in studies in France and Switzerland (P<0.01).
We suggest that this difference might be due to the use of different phenotyping procedures.
This is a preview of subscription content, log in via an institution to check access.
References
Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533–537
Andersson T, Reg⇘rdh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415–416
Andersson T, Reg⇘rdh CG, Lou Y-C, Zhang Y, Dahl ML, Bertilsson L (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in caucasian and chinese subjects. Pharmacogenetics 2:25–31
Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 45:348–355
Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, Wang K-Y, Reviriego J, Iselius L, Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish population in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388–397
Drøhse A, Bathum L, Brøsen K, Gram LF (1989) Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 27:620–625
Guttendorf RJ, Brito M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ (1990) Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. Br J Clin Pharmacol 29:373–380
Jacqz E, Hall SD, Branch RA, Wilkinson GR (1986) Polymorphic metabolism of mephenytoin in man; pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 39:646–653
Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167–171
Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p-(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19:483–487
Küpfer A, Roberts RK, Schenker S, Branch RA (1981) Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 218:193–199
Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753–759
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402–408
Sanz EJ, Villén T, Alm C, Bertilsson L (1989) S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after co-administration with debrisoquine. Clin Pharmacol Ther 45: 495–499
Skjelbo E, Brøsen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18–23
Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Molec Pharmacol 40:69–79
Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45: 72–79
Ward SA, Helsby NA, Skjelbo K, Brøsen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 31:689–692
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA (1984a) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773–780
Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR (1984b) Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 307:121–127
Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, Wilkinson GR (1985) Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 234: 662–669
Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA (1987) Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 15:277–279
Wilkinson GR, Guengerich FP, Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43: 53–76
Zhang Y, Reviriego J, Lou Y, Sjöqvist F, Bertilsson L (1990) Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects. Clin Pharmacol Ther 48:496–502
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reviriego, J., Bertilsson, L., Carrillo, J.A. et al. Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol 44, 593–595 (1993). https://doi.org/10.1007/BF02440867
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02440867